Compare

Monopar Therapeutics Inc./$MNPR

1D1W1M3M6MYTD1Y5YMAX

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Ticker
$MNPR
Sector
Health
Primary listing
NASDAQ
Employees
-
Headquarters
Wilmette, United States
Website
www.monopartx.com

MNPR Metrics

BasicAdvanced
$479M
-
-$2.18
1.51
-

Bulls say / Bears say

In Phase 3 FoCus analyses of patients with neurological symptoms, ALXN1840 led to less neurological worsening than standard care at Week 48 (9% versus 25%) and more global clinical improvement. That suggests it may offer a meaningful benefit for a difficult-to-treat group of Wilson disease patients. (Monopar Therapeutics)
The FDA has authorised a rolling NDA submission for ALXN1840, which Monopar began in July; the company expects to complete the application in the coming months. This moves its lead candidate towards a regulatory decision, although approval is not assured. (Monopar Therapeutics)
Monopar reported $134.3 million in cash, cash equivalents and investments at the end of June 2026 and expects those funds to cover operations through at least the end of 2027. That gives it time to pursue the ALXN1840 application and advance its radiopharmaceutical programmes without an immediate need for new funding. (Monopar Therapeutics)
ALXN1840’s regulatory path remains uncertain: Alexion ended its Wilson disease programme after mechanistic studies failed to show net-negative copper balance or reduced liver copper, despite the later Phase 3 trial meeting its primary endpoint. The FDA could require further studies or decline to approve the application. (U.S. Securities and Exchange Commission)
Monopar has no product revenue and continues to lose money; its second-quarter 2026 net loss widened to $5.3 million from $2.5 million a year earlier. The company says future funding needs may require additional capital, so shareholders could face dilution if operating costs outlast its current runway. (U.S. Securities and Exchange Commission)
The cancer radiopharmaceuticals remain early-stage, and Monopar flags uncertain isotope supply, manufacturing and market uptake as risks. Setbacks in these programmes could weaken the pipeline’s value before it can provide a commercial counterweight to ALXN1840. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.

MNPR Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

MNPR Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing MNPR

Funds
Fund name
Fund size
$MNPR weighting
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.01%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.